21.60

0.45% -0.03

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is traded at $21.60, with a volume of 554.05K. It is down -0.45% in the last 24 hours and up +21.31% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Previous Close:

$21.63

Open:

$21.96

24h Volume:

554.05K

Relative Volume:

0.35

Market Cap:

$2.41B

Revenue:

$-665.00K

Net Income/Loss:

$-150.11M

P/E Ratio:

-14.33

EPS:

-1.5071

Net Cash Flow:

$-124.53M

1W Performance:

-5.02%

1M Performance:

+21.31%

6M Performance:

+52.39%

1Y Performance:

+169.16%

1-Day Range:

$21.49

$22.47

1-Week Range:

$21.29

$24.08

52-Week Range:

$7.63

$24.60

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

617-682-0917

Address

55 CAMBRIDGE PARKWAY, CAMBRIDGE

Employee

136

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

AMLX's Discussions on Twitter

Compare AMLX vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMLX Amylyx Pharmaceuticals Inc	21.59	2.41B	-665.00K	-150.11M	-124.53M	-1.5071
TAK Takeda Pharmaceutical Co Adr	17.36	56.30B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.52	42.85B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.59	42.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.39	30.49B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	506.59	21.43B	3.17B	1.29B	1.01B	27.09

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-26	Initiated	Stifel	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Guggenheim	Buy
Jun-17-25	Initiated	Citigroup	Buy
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy
Mar-18-24	Downgrade	Mizuho	Buy → Neutral
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

08:11 AM

Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $30.00 - marketbeat.com

08:11 AM

07:38 AM

Mizuho raises Amylyx stock price target to $30 on higher pricing - Investing.com

07:38 AM

06:37 AM

Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $30 From $24, Keeps Outperform Rating - marketscreener.com

06:37 AM

Aug 15, 2026

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress - Yahoo Finance

Aug 15, 2026

Aug 14, 2026

Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Its Q2 Loss Update? - Yahoo Finance

Aug 14, 2026

Amylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III Update - Yahoo Finance

Aug 14, 2026

Aug 13, 2026

Amylyx (AMLX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 13, 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com

Aug 13, 2026

Aug 11, 2026

Is Amylyx (AMLX) Quietly Rewriting Its R&D Risk‑Reward Profile As Losses Deepen Without Revenue? - Sahm

Aug 11, 2026

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView

Aug 11, 2026

HC Wainwright Issues Pessimistic Outlook for AMLX Earnings - marketbeat.com

Aug 11, 2026

Aug 10, 2026

Weekly Recap: LUCIDITY trial completion and Q2 adjusted loss cut - TradingView

Aug 10, 2026

Aug 09, 2026

Dimensional Fund Advisors LP Has $12.54 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX - marketbeat.com

Aug 09, 2026